Gene Therapy

Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness

March 7, 2018

New nonprofit organization will bring treatments to clinical trial for people at risk for blindness due to ultra-rare inherited retinal diseases.

Luk Vandenberghe in laboratory

Boston, Mass. — Scientists and advocates today announced the formation of ...

Read more about Scientists, Advocates Team Up to Launch Odylia Therapeutics to Accelerate Gene Therapy Trials for Rare Conditions Causing Blindness
Luk Vandenberghe

Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear

May 19, 2016

Selecta is licensing Anc80 from Massachusetts Eye and Ear for a rare genetic disease with options on additional pre-specified indications. By combining Anc80 with Selecta’s investigational drug candidate, SVP-Rapamycin (SEL-110), Selecta is seeking to advance a new gene therapy platform designed to avoid several immunogenicity challenges that limit the development of gene therapies today 

Watertown, Mass. — Selecta Biosciences, Inc., a clinical-stage biopharmaceutical...

Read more about Selecta Biosciences obtains exclusive license to proprietary gene therapy vector from Massachusetts Eye and Ear